Editorial: The regulatory immune system as a target to improve adjuvants and novel vaccines.
作者信息
Jiménez-Cortegana Carlos, Poveda Cristina, Cabrera Gabriel
机构信息
Department of Medical Biochemistry, Molecular Biology and Immunology, Faculty of Medicine, University of Seville, Seville, Spain.
Department of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, United States.
出版信息
Front Cell Infect Microbiol. 2023 Jun 5;13:1223689. doi: 10.3389/fcimb.2023.1223689. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: The regulatory immune system as a target to improve adjuvants and novel vaccines.
Front Cell Infect Microbiol. 2023 Jun 5;13:1223689. doi: 10.3389/fcimb.2023.1223689. eCollection 2023.
2
Molecular adjuvants that modulate regulatory T cell function in vaccination: A critical appraisal.
Pharmacol Res. 2018 Mar;129:237-250. doi: 10.1016/j.phrs.2017.11.026. Epub 2017 Nov 22.
3
Vaccines and the regulatory arm of the immune system. An overview from the Trypanosoma cruzi infection model.
Vaccine. 2019 Jun 19;37(28):3628-3637. doi: 10.1016/j.vaccine.2019.05.015. Epub 2019 May 31.
4
Myeloid-derived suppressor cells and vaccination against pathogens.
Front Cell Infect Microbiol. 2022 Sep 29;12:1003781. doi: 10.3389/fcimb.2022.1003781. eCollection 2022.
5
Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells.
Immunol Cell Biol. 2013 Jan;91(1):105-14. doi: 10.1038/icb.2012.58. Epub 2012 Oct 23.
6
A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4 CD25 FOXP3 Regulatory T Cells in Myelin-Specific TCR Transgenic Mice Contingent Upon Low-Efficiency T Cell Antigen Receptor Recognition.
Front Immunol. 2019 Jan 10;9:3119. doi: 10.3389/fimmu.2018.03119. eCollection 2018.
7
Current adjuvants and new perspectives in vaccine formulation.
Expert Rev Vaccines. 2011 Jul;10(7):1053-61. doi: 10.1586/erv.11.48.
8
How do adjuvants work? Important considerations for new generation adjuvants.
Immunity. 2007 Nov;27(5):687-90. doi: 10.1016/j.immuni.2007.11.003.
9
Vaccine adjuvants: smart components to boost the immune system.
Arch Pharm Res. 2017 Nov;40(11):1238-1248. doi: 10.1007/s12272-017-0969-z. Epub 2017 Oct 13.
10
Targeting Myeloid-Derived Suppressor Cells to Enhance a Trans-Sialidase-Based Vaccine Against .
Front Cell Infect Microbiol. 2021 Jul 6;11:671104. doi: 10.3389/fcimb.2021.671104. eCollection 2021.
本文引用的文献
1
Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells.
Int J Mol Sci. 2023 Mar 8;24(6):5208. doi: 10.3390/ijms24065208.
2
Dendritic cell subsets in cancer immunity and tumor antigen sensing.
Cell Mol Immunol. 2023 May;20(5):432-447. doi: 10.1038/s41423-023-00990-6. Epub 2023 Mar 22.
3
Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches.
Pharmaceutics. 2022 Aug 17;14(8):1721. doi: 10.3390/pharmaceutics14081721.
4
Myeloid-Derived Suppressor Cells and Radiotherapy.
Cancer Immunol Res. 2022 May 3;10(5):545-557. doi: 10.1158/2326-6066.CIR-21-1105.
5
Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives.
Cells. 2021 Dec 22;11(1):20. doi: 10.3390/cells11010020.
6
Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial.
Cancers (Basel). 2021 Sep 15;13(18):4622. doi: 10.3390/cancers13184622.
7
Dendritic cell migration in inflammation and immunity.
Cell Mol Immunol. 2021 Nov;18(11):2461-2471. doi: 10.1038/s41423-021-00726-4. Epub 2021 Jul 23.
8
Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer.
Sci Rep. 2021 Jul 13;11(1):14426. doi: 10.1038/s41598-021-93838-w.
9
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial.
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2020-002323.
10
Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer.
Cells. 2021 Feb 5;10(2):329. doi: 10.3390/cells10020329.
Zotero 插件